Psoriatic Arthritis in Black Patients: Signs, Delays, Care

Psoriatic arthritis (PsA) is an inflammatory arthritis that goes along with psoriasis. The immune system attacks the joints and the spots where tendons attach to bone, causing pain, swelling, and stiffness that can become permanent. It can start years after psoriasis appears on the skin, or it can show up first, before any rash. In Black patients, psoriasis is often missed because it looks different on dark skin, so the arthritis that follows gets diagnosed late, after damage has already started.

PsA affects the joints, the skin, and the eyes. The patterns to know:

• Joint pain and swelling. Often in the fingers, toes, knees, ankles, or lower back. It can be on one side of the body rather than mirrored on both.
• Dactylitis (sausage digits). A whole finger or toe swells, not just one knuckle. This is close to a signature sign of PsA.
• Enthesitis. Pain where tendons meet bone, most often the back of the heel (Achilles) or the bottom of the foot.
• Nail changes. Pitting, crumbling, white spots, or the nail lifting off its bed.
• Stiffness. Morning stiffness that lasts longer than 30 minutes and eases with movement, not rest.
• Fatigue. A deep tiredness driven by inflammation, not just poor sleep.
• Eye inflammation (uveitis). A red, painful, light-sensitive eye. Roughly 7 to 25 percent of people with PsA develop it, per the American College of Rheumatology.

Most medical training shows psoriasis as bright-red, scaly patches. On Black skin it rarely looks that way. Inflammation appears violaceous, dark brown, or gray rather than red, and active plaques can be mistaken for ordinary dark marks or post-inflammatory hyperpigmentation. A 2022 review in Drugs in Context found that plaques on darker skin tend to be thicker with more scale and cover a larger area: African Americans average 3 to 10 percent of their body surface affected, compared with 1 to 2 percent in White patients. When the skin disease is downplayed, the joint disease that travels with it gets taken less seriously too. Even after the rash clears, the dark marks it leaves behind can take years to fade.

If you have unexplained dark, scaly patches on your scalp, elbows, knees, or around your nails plus joint pain, those two things may be one diagnosis. Our guide to psoriasis on Black skin covers what the rash actually looks like and how to get it read correctly.

PsA is recorded less often in Black patients, but that gap is partly diagnostic, not biological. When it is present, it tends to hit harder and get treated less. In a study of psoriasis and PsA patients at a Washington, D.C. medical center, African American patients had higher skin-severity scores (a PASI of 8.4 versus 5.5) along with greater psychological impact and worse quality of life, yet only 13.3 percent received biologic therapy compared with 46.2 percent of White patients.

The pattern holds in larger datasets. A 2023 Medicaid claims study of newly diagnosed PsA found Black patients started any DMARD therapy within a year less often than White patients (68.4 versus 76.4 percent) and started biologics less often (33.6 versus 42.6 percent), with significantly longer delays to treatment after diagnosis. A 2024 National Health and Wellness Survey analysis found Black patients reported nearly double the work absenteeism of White patients (31.1 versus 16.7 percent) while making fewer healthcare visits and far fewer rheumatologist visits. More disease, more life disruption, less specialist care.

Coverage shapes access too. A 2021 analysis found that among Medicaid enrollees with PsA, biologic use was lower for Black patients (29 percent) than White patients (45 percent), while commercial-insurance rates were close. The takeaway is not that the disease spares Black patients. It is that diagnosis comes late, specialists are harder to reach, and the strongest treatments reach fewer people. PsA shares this access gap with other inflammatory diseases; see our coverage of rheumatoid arthritis in Black patients.

There is no single blood test for PsA. A rheumatologist makes the diagnosis from the pattern: psoriasis (current, past, or a family history), the joints involved, dactylitis, enthesitis, and nail disease. Imaging helps. X-rays can show characteristic joint damage, and ultrasound or MRI can catch inflammation before it shows on an X-ray. Blood work mainly rules out look-alikes: rheumatoid factor is usually negative in PsA (which helps separate it from rheumatoid arthritis), and uric acid and joint-fluid testing help rule out gout. Because the skin clue is so easy to miss on dark skin, tell your doctor directly if you have ever had scaly patches or nail changes, even old ones that cleared.

Treatment is staged to how active the disease is. NSAIDs (ibuprofen, naproxen) ease mild joint pain but do not stop damage. Conventional DMARDs such as methotrexate calm the immune system and are often the next step. Biologics and targeted drugs, including TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors, block the specific immune signals driving PsA and can both protect joints and clear skin. The goal is to stop inflammation early, because joint erosion does not reverse. Damage that has already happened stays. That is why the diagnostic delay documented in Black patients is not a paperwork problem: every month of untreated inflammation is a month of permanent change to the joint.

Start with a primary care visit and name both problems in one sentence: the joint pain and any history of scaly patches or nail changes. Ask directly for a referral to a rheumatologist, the specialist who diagnoses and manages PsA, and a dermatologist for the skin. Bring photos of any rash or nail changes, including ones that have cleared, since the visual clue is easy to overlook on dark skin. If you want a clinician who understands how this disease presents on Black skin, you can find a Black rheumatologist or dermatologist in our directory. The single most useful thing you can do is push for the specialist referral early, before the joints are damaged.